Pre-existing TCR clones drive major pathological responses in HNSCC patients treated with dual immune checkpoint inhibitors
Dual ICI drives MPR predominantly through the adaptivity and functional reprogramming of pre-existing immunity. Successful therapy relies on a coordinate repertoire response that promotes transition of putative tumor-reactive super-expanders into productive functional states. TRS-integrated TAI provides a high-throughput framework incorporating clonal dynamics and functional reprogramming to predict therapeutic efficacy.
Authors
- Huaibin Ge (ORCID: https://orcid.org/0000-0002-4726-7023)
- Z Chen
- Aditi Kulkarni (ORCID: https://orcid.org/0000-0002-4886-6095)
- Robert L. Ferris (ORCID: https://orcid.org/0000-0001-6605-2071)
- Jing H. Wang
- Pragati Upadhyay
- Housaiyin Li
Institutions
- University of North Carolina at Chapel Hill (US)
- University of Pittsburgh (US)
- University of North Carolina Hospitals (US)
- UPMC Hillman Cancer Center (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2026-03-05
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-3749
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00